Literature DB >> 6284663

A review of recent contributions on biologically active products of arachidonate conversion.

R A Lewis, J M Drazen, J C Figueiredo, E J Corey, K F Austen.   

Abstract

Leukotrienes (LTs) C4, D4 and E4, the recognized components of slow reacting substance of anaphylaxis (SRS-A), have previously been shown to have contractile activities for guinea pig pulmonary and ileal smooth muscles; LTB4 has been shown to possess chemotactic activity for neutrophils in vitro. Based on data obtained by the use of structural analogs of the SRS-A LTs and of LTB4, we have recently determined a number of the structural bases for the biological function of each moiety. With regard to the SRS-A leukotrienes, analogs differed from the native structures in the position of the peptide side chain and/or the hydroxyl group, the number and position of ethylenic bonds, the chirality at optically-active centers, or the structures of the four polar substituents in the C-1 to C-6 region. Analogs of LTB4, differing in the stereochemistry of their ethylenic bonds, were evaluated for chemotactic activity both in vitro, using human neutrophils, and in vivo intracutaneously in the rhesus monkey. We propose that true receptors exist on the pulmonary parenchyma of the guinea pig for the SRS-A LTs and on the primate neutrophil for LTB4. Further, LTC4, LTD4 and LTE4 have been shown to elicit a wheal and prolonged flare in human skin, whereas LTB4 evokes a time-dependent induration. The interaction of these secondary mediators may be critical to a fully developed host inflammatory response to both immunologic and non-immunologic injury.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284663     DOI: 10.1016/0192-0561(82)90055-8

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  10 in total

Review 1.  Pharmacological studies of pulmonary anaphylaxis in vitro: a review.

Authors:  P O Ogunbiyi; P Eyre
Journal:  Agents Actions       Date:  1985-12

2.  A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists.

Authors:  V Hariprasad; V M Kulkarni
Journal:  J Comput Aided Mol Des       Date:  1996-08       Impact factor: 3.686

3.  The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction.

Authors:  I Joris; G Majno; E J Corey; R A Lewis
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

Review 4.  Metabolism of leukotrienes.

Authors:  S Hammarström; L Orning; K Bernström
Journal:  Mol Cell Biochem       Date:  1985-11       Impact factor: 3.396

5.  The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig.

Authors:  J R Boot; A Bond; R Gooderham; A O'Brien; M Parsons; K H Thomas
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

6.  Arachidonic acid metabolism in normal and hypereosinophilic syndrome human eosinophils: generation of leukotrienes B4, C4, D4 and 15-lipoxygenase products.

Authors:  W R Henderson; J B Harley; A S Fauci
Journal:  Immunology       Date:  1984-04       Impact factor: 7.397

7.  Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors.

Authors:  T H Lee; K F Austen; E J Corey; J M Drazen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

Review 8.  Leukotrienes, allergy and inflammation.

Authors:  F P Nijkamp; J M Sitsen
Journal:  Pharm Weekbl Sci       Date:  1982-12-17

9.  Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes.

Authors:  C W Lee; R A Lewis; E J Corey; K F Austen
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

Review 10.  Immunologic mechanisms of parenchymal lung injury.

Authors:  W F Willoughby; J B Willoughby
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.